🇺🇸 GILD — Gilead Sciences, Inc.

Healthcare Compra
← Volver

Precio actual

151,00 USD

Máx. histórico

157,29

205 días

Caída desde máximo

-4,00%

Rango 52 semanas

108,46 – 157,29

Variación hoy

-0,15%

Cierre anterior

151,22

Rango de hoy

149,23 – 151,19

Volumen hoy

5.977.099

Información
Nombre completo
Gilead Sciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
17.000
PER
Dividend yield
2,17% (puede no estar actualizado)
Precio objetivo analistas
157,41 USD (puede no estar actualizado)
Primera cotización
22/01/1992
Precio actualizado
hace 1 día
Sobre la empresa

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Dividendos repartidos Total últimos 12 meses: 3,2200 USD · Yield: 2,13%
Fecha de pago Importe por participación
14/09/2022 0,7300 USD
14/06/2022 0,7300 USD
14/03/2022 0,7300 USD
14/12/2021 0,7100 USD
14/09/2021 0,7100 USD
14/06/2021 0,7100 USD
12/03/2021 0,7100 USD
14/12/2020 0,6800 USD
14/09/2020 0,6800 USD
11/06/2020 0,6800 USD
12/03/2020 0,6800 USD
12/12/2019 0,6300 USD
12/09/2019 0,6300 USD
13/06/2019 0,6300 USD
14/03/2019 0,6300 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/03/2024 72,28 72,66 72,04 72,31 +0,29% 0,86% 5.401.200
29/02/2024 72,72 72,91 71,92 72,10 -0,83% 1,36% 8.583.200
28/02/2024 73,18 73,25 72,61 72,70 -0,44% 0,87% 4.245.600
27/02/2024 72,85 73,14 72,63 73,02 +0,10% 0,70% 6.090.400
26/02/2024 73,50 73,89 72,84 72,95 -0,82% 1,43% 5.177.900
23/02/2024 73,25 74,24 73,00 73,55 +1,06% 1,69% 5.573.500
22/02/2024 72,26 72,89 71,83 72,78 -0,57% 1,47% 7.323.600
21/02/2024 72,51 73,29 72,51 73,20 +1,61% 1,08% 6.233.300
20/02/2024 71,59 72,73 71,45 72,04 +0,64% 1,79% 7.874.200
16/02/2024 73,00 73,09 71,37 71,58 -2,44% 2,36% 12.823.200
15/02/2024 73,04 73,57 72,81 73,37 +0,45% 1,04% 5.482.900
14/02/2024 73,11 73,83 72,83 73,04 -0,67% 1,37% 7.487.700
13/02/2024 74,69 74,77 72,97 73,53 -1,24% 2,41% 8.560.100
12/02/2024 73,41 75,14 73,11 74,45 +1,06% 2,77% 7.605.800
09/02/2024 73,82 74,12 72,81 73,67 -0,18% 1,77% 10.718.300
08/02/2024 74,40 74,59 73,03 73,80 -0,83% 2,10% 8.815.200
07/02/2024 76,21 76,45 73,94 74,42 -4,25% 3,29% 12.449.800
06/02/2024 76,87 77,87 76,71 77,72 +1,32% 1,51% 8.121.200
05/02/2024 76,65 77,05 76,01 76,71 -0,32% 1,36% 6.690.400
02/02/2024 77,61 77,99 76,91 76,96 -1,54% 1,39% 7.588.800
01/02/2024 78,00 78,58 77,40 78,16 -0,13% 1,51% 7.698.000
31/01/2024 78,79 79,03 78,01 78,26 -0,46% 1,29% 7.637.300
30/01/2024 78,80 78,90 77,96 78,62 -0,57% 1,19% 8.102.400
29/01/2024 79,65 80,01 78,91 79,07 -0,57% 1,38% 6.586.000
26/01/2024 80,23 80,51 79,40 79,52 -0,88% 1,38% 5.481.400
25/01/2024 80,08 81,06 79,55 80,23 +0,88% 1,89% 8.337.400
24/01/2024 79,56 79,90 78,48 79,53 +0,06% 1,78% 7.563.000
23/01/2024 78,54 79,88 78,39 79,48 +1,34% 1,90% 7.837.600
22/01/2024 80,50 80,75 77,37 78,43 -10,15% 4,20% 20.378.600
19/01/2024 86,38 87,87 86,09 87,29 +1,03% 2,06% 6.400.700